“Marginal Zone Lymphoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Marginal Zone Lymphoma Market.
The Marginal Zone Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Marginal Zone Lymphoma Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Marginal Zone Lymphoma treatment therapies with a considerable amount of success over the years.
-
Marginal Zone Lymphoma companies working in the treatment market are Carna Biosciences, Hutchmed, Incyte, Innovent, MorphoSys, Beigene, InnoCare Pharma, Beijing Mabworks Biotech Co., MEI Pharma, Inc., Kyowa Kirin, ADC Therapeutics, Loxo Oncology, Adicet Bio, Celldex Therapeutics Inc, and others, are developing therapies for the Marginal Zone Lymphoma treatment
-
Emerging Marginal Zone Lymphoma therapies in the different phases of clinical trials are- AS-1763, Amdizalisib (HMPL689), Parsaclisib (IBI376), Tafasitamab, Zanubrutinib, Orelabrutinib, Tafasitamab, MIL62, Zandelisib, Loncastuximab, LOXO-305, ADI-001, CDX-1140, and others are expected to have a significant impact on the Marginal Zone Lymphoma market in the coming years.
-
In August 2025, The US FDA has granted priority review to the supplemental biologics license application (sBLA) for lisocabtagene maraleucel (liso-cel; Breyanzi), a CD19-targeted CAR T-cell therapy, for treating marginal zone lymphoma (MZL).
-
In August 2025, The FDA has accepted Bristol Myers Squibb’s supplemental biologics license application (sBLA) for lisocabtagene maraleucel (liso-cel, Breyanzi), an autologous CD19-directed CAR T-cell therapy, for marginal zone lymphoma (MZL) with priority review. The Prescription Drug User Fee Act (PDUFA) target date is December 5, 2025. This sBLA is being evaluated for adults with relapsed/refractory (R/R) MZL who have undergone two or more prior systemic therapies and is supported by data from the Phase 2 TRANSCEND FL trial (NCT04245839).
-
In June 2025, A poster presentation at the ICML 2025 Congress highlighted the potential of combining rituximab and ibrutinib to treat marginal zone lymphoma (MZL). Currently, no standard frontline therapies exist for MZL patients. Previous studies have shown that BTK inhibitors offer a favorable risk-benefit profile for relapsed MZL across subtypes, including splenic (SMZL) and nodal (NMZL) forms. The phase II IELSG47/MALIBU trial evaluated the efficacy and safety of the rituximab and ibrutinib combination in treating MZL.
-
In February 2025, Bristol Myers Squibb (NYSE: BMY) announced that the Phase 2 TRANSCEND FL trial evaluating Breyanzi® (lisocabtagene maraleucel) in adult patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma achieved its primary endpoint in the marginal zone lymphoma (MZL) cohort. The results indicated that Breyanzi delivered a statistically significant and clinically meaningful overall response rate (ORR) in these patients.
-
In January 2025, Verismo Therapeutics, a clinical-stage CAR T company specializing in KIR-CAR platform technology, announced the dosing of the first patient in its CELESTIAL-301 Phase 1 clinical trial. The infusion took place at the Sarah Cannon Research Institute (SCRI) at Colorado Blood Cancer Institute (CBCI) in Denver, Colorado. The CELESTIAL-301 trial is designed to evaluate the safety, tolerability, and preliminary efficacy of SynKIR™-310 in patients with relapsed/refractory (r/r) B-cell Non-Hodgkin Lymphomas (B-cell NHL), including Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Marginal Zone Lymphoma (MZL). This Phase 1 multicenter trial is enrolling patients who have previously undergone CAR T therapy but relapsed or became refractory, as well as those who have never received CAR T therapy.
-
In August 2024, The UK National Institute for Health and Care Excellence (NICE) has endorsed BeiGene's Zanubrutinib (Brukinsa) for treating marginal zone lymphoma (MZL), a form of blood cancer, within the National Health Service (NHS). This approval introduces a new treatment option for patients in England, with the potential to slow cancer progression and reduce the need for additional chemotherapy.
-
In May 2024, ADC Therapeutics SA (NYSE: ADCT) has disclosed that preliminary findings from an investigator-launched Phase 2 clinical study assessing ZYNLONTA® (loncastuximab tesirine-lpyl) revealed a significant response rate among patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL).
-
In April 2024, Verismo Therapeutics, a clinical-stage CAR T company pioneering the innovative KIR-CAR platform technology, has announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its Phase 1 clinical trial of SynKIR™-310. This trial aims to evaluate the efficacy of SynKIR™-310 in treating relapsed/refractory (r/r) B-cell Non-Hodgkin Lymphomas (B-cell NHL), which includes Diffuse Large B Cell lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Marginal Zone Lymphoma (MZL).
-
In March 2024, InnoCare Pharma has obtained approval for an investigational new drug application to commence a clinical study evaluating ICP-248 combined with orelabrutinib in China for the treatment of lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Marginal Zone Lymphoma Overview
Marginal Zone Lymphoma is a slow-growing type of non-Hodgkin lymphoma that originates from B-cells in the marginal zone of lymphoid tissues. It commonly affects the spleen, lymph nodes, or mucosa-associated lymphoid tissue (MALT). MZL often presents with painless swelling and may be linked to chronic infections or autoimmune disorders. Treatment varies based on the subtype and disease stage, ranging from watchful waiting to chemotherapy or targeted therapies.
Get a Free Sample PDF Report to know more about Marginal Zone Lymphoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/marginal-zone-lymphoma-pipeline-insight
Emerging Marginal Zone Lymphoma Drugs Under Different Phases of Clinical Development Include:
-
AS-1763: Carna Biosciences
-
Amdizalisib (HMPL689): Hutchmed
-
Parsaclisib (IBI376): Incyte/Innovent
-
Tafasitamab: MorphoSys/Incyte
-
Zanubrutinib: Beigene
-
Orelabrutinib: InnoCare Pharma
-
Tafasitamab: Incyte Corporation
-
MIL62: Beijing Mabworks Biotech Co.
-
Zandelisib: MEI Pharma, Inc./Kyowa Kirin
-
Loncastuximab: ADC Therapeutics
-
LOXO-305: Loxo Oncology
-
ADI-001: Adicet Bio
-
CDX-1140: Celldex Therapeutics Inc
Marginal Zone Lymphoma Route of Administration
Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Inhalation
-
Inhalation/Intravenous/Oral
-
Intranasal
-
Intravenous
-
Intravenous/ Subcutaneous
-
NA
-
Oral
-
Oral/intranasal/subcutaneous
-
Parenteral
-
Subcutaneous
Marginal Zone Lymphoma Molecule Type
Marginal Zone Lymphoma Products have been categorized under various Molecule types, such as
-
Antibody
-
Antisense oligonucleotides
-
Immunotherapy
-
Monoclonal antibody
-
Peptides
-
Protein
-
Recombinant protein
-
Small molecule
-
Stem Cell
-
Vaccine
Marginal Zone Lymphoma Pipeline Therapeutics Assessment
-
Marginal Zone Lymphoma Assessment by Product Type
-
Marginal Zone Lymphoma By Stage and Product Type
-
Marginal Zone Lymphoma Assessment by Route of Administration
-
Marginal Zone Lymphoma By Stage and Route of Administration
-
Marginal Zone Lymphoma Assessment by Molecule Type
-
Marginal Zone Lymphoma by Stage and Molecule Type
DelveInsight's Marginal Zone Lymphoma Report covers around 50+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Marginal Zone Lymphoma product details are provided in the report. Download the Marginal Zone Lymphoma pipeline report to learn more about the emerging Marginal Zone Lymphoma therapies
Some of the key companies in the Marginal Zone Lymphoma Therapeutics Market include:
Key companies developing therapies for Marginal Zone Lymphoma are - Incyte Corporation, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Incyte Corporation, Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc, Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, and others.
Marginal Zone Lymphoma Pipeline Analysis:
The Marginal Zone Lymphoma pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Marginal Zone Lymphoma with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Marginal Zone Lymphoma Treatment.
-
Marginal Zone Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Marginal Zone Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Marginal Zone Lymphoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Marginal Zone Lymphoma drugs and therapies
Marginal Zone Lymphoma Pipeline Market Drivers
-
Increasing Prevalence, increased research and development are some of the important factors that are fueling the Marginal Zone Lymphoma Market.
Marginal Zone Lymphoma Pipeline Market Barriers
-
However, therapies with moderately good patient outcomes, long treatment course and other factors are creating obstacles in the Marginal Zone Lymphoma Market growth.
Scope of Marginal Zone Lymphoma Pipeline Drug Insight
-
Coverage: Global
-
Key Marginal Zone Lymphoma Companies: Carna Biosciences, Hutchmed, Incyte, Innovent, MorphoSys, Beigene, InnoCare Pharma, Beijing Mabworks Biotech Co., MEI Pharma, Inc., Kyowa Kirin, ADC Therapeutics, Loxo Oncology, Adicet Bio, Celldex Therapeutics Inc, and others
-
Key Marginal Zone Lymphoma Therapies: AS-1763, Amdizalisib (HMPL689), Parsaclisib (IBI376), Tafasitamab, Zanubrutinib, Orelabrutinib, Tafasitamab, MIL62, Zandelisib, Loncastuximab, LOXO-305, ADI-001, CDX-1140, and others
-
Marginal Zone Lymphoma Therapeutic Assessment: Marginal Zone Lymphoma current marketed and Marginal Zone Lymphoma emerging therapies
-
Marginal Zone Lymphoma Market Dynamics: Marginal Zone Lymphoma market drivers and Marginal Zone Lymphoma market barriers
Request for Sample PDF Report for Marginal Zone Lymphoma Pipeline Assessment and clinical trials
Table of Contents
1. Marginal Zone Lymphoma Report Introduction
2. Marginal Zone Lymphoma Executive Summary
3. Marginal Zone Lymphoma Overview
4. Marginal Zone Lymphoma- Analytical Perspective In-depth Commercial Assessment
5. Marginal Zone Lymphoma Pipeline Therapeutics
6. Marginal Zone Lymphoma Late Stage Products (Phase II/III)
7. Marginal Zone Lymphoma Mid Stage Products (Phase II)
8. Marginal Zone Lymphoma Early Stage Products (Phase I)
9. Marginal Zone Lymphoma Preclinical Stage Products
10. Marginal Zone Lymphoma Therapeutics Assessment
11. Marginal Zone Lymphoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Marginal Zone Lymphoma Key Companies
14. Marginal Zone Lymphoma Key Products
15. Marginal Zone Lymphoma Unmet Needs
16 . Marginal Zone Lymphoma Market Drivers and Barriers
17. Marginal Zone Lymphoma Future Perspectives and Conclusion
18. Marginal Zone Lymphoma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
